1-3 of 3
Emanuela Marchesini
Close
Sort by
Journal Articles

Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study

Davide Matino, MD MSc, Giancarlo Castaman, Giovanni Di Minno, Paola Giordano, MD, Maria Elisa Mancuso, Emanuela Marchesini, Flora Peyvandi, MD PhD, Elena Santagostino, Cristina Santoro, MD PhD, Michele Schiavulli, Antonella De Luca, PhD, Marco Gargaro, Paolo Puccetti, MD, Francesca Fallarino, PhD, Alfonso Iorio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3781.
https://doi.org/10.1182/blood-2018-99-119568
Published: 2018
Journal Articles

Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies

Clinical Trials & Observations
Matteo Nicola Dario Di Minno, Emanuela Marchesini, Lelia Valdrè
Journal: Blood
Blood (2015) 125 (24): 3819–3821.
https://doi.org/10.1182/blood-2015-01-621383
Published: 2015
Journal Articles

Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.

Alfonso Iorio, MD, Susan Halimeh, MD, Christoph Bidlingmaier, MD, Leonardo R. Brandao, MD, Carmen Escuriola-Ettingshausen, MD, Neil A Goldenberg, MD, PhD, Alessandro Gringeri, MD, MSc, Susanne Holzhauer, MD, Gili Kenet, MD, PhD, Ralf Knoefler, MD, Wolfhart Kreuz, MD, Karin Kurnik, MD, Daniela Manner, MD, Emanuela Marchesini, MD, Maura Marcucci, MD, Elena Santagostino, MD, PhD, Guy Young, MD, Pier Mannuccio Mannucci, MD, Ulrike Nowak-Gottl, MD
Journal: Blood
Blood (2009) 114 (22): 3154.
https://doi.org/10.1182/blood.V114.22.3154.3154
Published: 2009